For Indian pharma, AI’s efficiency payoff is in the two things that dominate the industry’s economics — discovery and trial timelines — plus tighter manufacturing, all within GxP. Here’s where to capture it. (dgm implements osFoundry, a separate company’s platform — dgm is an independent integration partner, not osFoundry, and this is not regulatory advice.)

Where the gains are

  • Discovery — faster candidate identification, narrowing the search earlier.
  • Clinical trials — protocol design, site selection and recruitment cut timelines, India’s diversity an asset.
  • Document-heavy processes — pharmacovigilance case processing, medical-content drafting, regulatory submissions.
  • GxP manufacturing — deviation prediction and process optimisation reducing waste.

Trials and discovery are where time savings translate most directly into time-to-market and R&D-cost advantage — the biggest levers in pharma economics.

Efficiency within GxP and data integrity

The constraint is non-negotiable: efficiency automation must preserve audit trails, validation, and authorised human review before AI output becomes a controlled record — reinforced by the 2026 FDA warning letter on AI in cGMP documentation (see AI in pharma in India). Speed cannot compromise these controls, or the gain becomes a liability.

Start with document-heavy, lower-risk processes

The disciplined entry point is document-heavy, lower-risk work — pharmacovigilance case processing, medical-content drafting, and regulatory-submission support. These have high manual volume and clear governance patterns, so they deliver gains while keeping human review intact. Prove value there, then extend to higher-stakes discovery and manufacturing uses.

Where osFoundry fits

osFoundry supports these document and operational workflows — retrieval, drafting, PV processing — with an audit and human-review layer and self-hosting for IP and data control. dgm builds the controls; your QA/regulatory team owns GxP determinations. osFoundry is younger with limited independent coverage, so dgm validates the build.

How dgm helps

dgm targets document-heavy and operational processes first, builds them on osFoundry with audit and human-in-the-loop controls, self-hosted for IP and data control, and expands on proven value. Transparent pricing: $399 assessment, $3,999/month implementation, no per-seat fees (INR approximate; 18% GST for domestic clients). Explore the platform at osFoundry, or talk to dgm about pharma efficiency.

General information, not regulatory advice. Confirm CDSCO, GxP and FDA obligations with qualified experts before deploying.